Neurocristopathy

This study tests whether a special PET scan (68Ga-CTR-FAPI) can help surgeons remove all medullary thyroid cancer during the first surgery, aiming for a cure. About 150 newly diagnosed patients will be split into two groups: one gets surgery guided by the new scan, the other gets…

This early-phase trial tests a new mRNA vaccine called PAN-NeoVax, designed by artificial intelligence to target multiple cancer types. The vaccine is injected directly into tumors in 9 patients with advanced solid cancers who have run out of standard options. The main goal is to…

This early-stage trial tests whether a stool transplant (FMT) can help cancer patients who develop severe diarrhea or colon inflammation from immune-checkpoint inhibitor drugs. About 40 patients with various cancers will receive the transplant via colonoscopy. The main goal is to…

This early-phase trial is testing an experimental drug called BI-1808, alone or with the immunotherapy pembrolizumab (Keytruda), in people with advanced cancers like ovarian cancer, T-cell lymphoma, and melanoma. The main goals are to check safety, find the best dose, and see how…

This early-stage trial is testing whether an oral probiotic called R-5780 is safe and tolerable when taken alongside a standard PD-1 checkpoint inhibitor in people with advanced solid tumors (like melanoma or certain skin cancers). About 33 adults whose cancer has not responded t…

This study tests a new drug called AU-007 in people with advanced solid tumors that have spread or cannot be removed by surgery. The drug is designed to help the immune system fight cancer. About 159 participants will receive AU-007 alone or with other medicines to find the safes…

This phase 2 trial tests enasidenib, a daily pill that targets the IDH2 gene mutation, in 40 adults with rare cancers of the nasal cavity or skull base that have spread or come back. Participants take the drug once daily in 28-day cycles, and researchers will track how long the c…

This phase II trial is testing whether the combination of cabozantinib (a targeted therapy) and nivolumab (an immunotherapy) can shrink or stabilize advanced melanoma and head and neck cancers that have stopped responding to prior immunotherapy. Researchers are also checking if t…

This phase 2 trial is testing an experimental drug called patritumab deruxtecan (HER3-DXd) in 740 people with advanced solid tumors, including melanoma, lung, breast, and other cancers. The drug is given by IV every three weeks. The main goal is to see if the drug shrinks tumors.…

This early-stage study tests a new drug called N-3C01, given alone or with an immunotherapy, in people with advanced solid tumors that have spread or cannot be removed. The main goals are to check safety, find the right dose, and see if the combination shrinks tumors. About 114 a…

This study tests a drug called ifinatamab deruxtecan (I-DXd) in children with solid tumors that have returned or not responded to treatment. The drug is an antibody-drug conjugate that targets cancer cells directly. The trial aims to check safety and see if tumors shrink in about…

This study tests a drug called zilovertamab vedotin in children and young adults whose blood cancers (like certain leukemias and lymphomas) or solid tumors (neuroblastoma, Ewing sarcoma) have come back or not responded to treatment. The goal is to see if the drug is safe and can …

This study tests whether adding the drug dinutuximab to standard chemotherapy and other treatments helps children with high-risk neuroblastoma live longer without their cancer returning. About 478 children and young adults up to age 30 will be randomly assigned to receive either …

This study tests whether adding the drug naxitamab to standard chemotherapy is safe and effective for children and young adults newly diagnosed with high-risk neuroblastoma, an aggressive nerve cell cancer. Ten participants aged 1 to 21 will receive the combination and be monitor…

This Phase 2 trial tests whether combining pembrolizumab (an immunotherapy) with aldesleukin (IL-2) can shrink tumors in people with advanced melanoma or kidney cancer that hasn't responded to prior treatments. About 78 adults will receive two cycles of the combo in the hospital,…

This phase 2 trial tests a drug called BMS-986504 in people with advanced solid tumors that have lost a gene called MTAP. The drug is given alone or with other cancer medicines. The study aims to see if the drug shrinks tumors and how safe it is. About 260 adults will take part.

This early-phase trial tests whether giving different drug combinations after surgery, based on how well the tumor responded to initial treatment, can reduce the risk of melanoma returning. About 50 adults with stage III or IV BRAF-mutant melanoma will receive encorafenib, binime…

This early-stage trial is testing a new drug called BL-M14D1 in about 120 people with advanced small cell lung cancer or other neuroendocrine cancers that have spread or cannot be removed. The drug works by homing in on a protein called DLL3 found on these cancer cells and delive…

This study is testing whether giving lower, less frequent doses of the cancer drug atezolizumab can still keep enough drug in the blood to fight cancer. About 30 adults with certain advanced cancers (like lung cancer or melanoma) will start with standard doses, then switch to a l…

This study tests the drug abemaciclib, typically used for cancer, in people with neurofibromatosis type 1 (NF1) who have atypical neurofibromas that cannot be surgically removed. The goal is to find a safe dose and see if it can shrink or stabilize these tumors. Participants take…

This study tests an oral drug called NEO212 in people with specific brain tumors (astrocytoma, glioblastoma) or cancers that have spread to the brain. The goal is to find the safest dose and see if it helps control tumor growth. About 134 adults will take NEO212 alone or with sta…

This phase 3 trial tests whether taking darovasertib and crizotinib after standard treatment can delay or prevent uveal melanoma from returning. The study enrolls adults with high-risk, non-metastatic uveal melanoma who have completed local therapy such as surgery or radiation. P…

This phase 2 trial is testing a drug called tebentafusp in 19 people with a rare eye cancer (uveal melanoma) that has spread to the liver. Participants receive weekly infusions for 6 months, then may have surgery to remove any remaining tumors. The goal is to see if the drug can …

This study provides continued access to dabrafenib and/or trametinib for up to 100 patients with melanoma, lung cancer, or other solid tumors who were benefiting from these drugs in a prior Novartis or GSK trial. The main goal is to track long-term side effects and safety over ti…

This early-stage trial tests a personalized cell therapy called lifileucel for people with advanced uveal melanoma (a rare eye cancer) or certain sarcomas (connective tissue cancers). The treatment involves removing immune cells from the patient's tumor, growing them in a lab, an…

This study tests whether adding a fecal microbiota transplant called LND101 to standard immunotherapy can help stop advanced melanoma from growing or spreading. About 128 people with stage IV or unresectable melanoma will receive either immunotherapy alone or immunotherapy plus L…

This early-phase trial tests SL-28, a cell therapy made from donor immune cells, in 60 people with advanced solid tumors (like lung, pancreatic, or breast cancer) that haven't responded to standard treatments. The study aims to find a safe dose and see if the therapy can shrink t…

This phase 2 trial compares two treatment combinations for people with BRAF-V600 mutant melanoma that has spread to the brain. One group gets a targeted therapy (encorafenib and binimetinib) plus an immunotherapy (nivolumab), while the other gets two immunotherapies (ipilimumab a…

This early-phase trial tests a new drug called BI 3810944 in adults with advanced solid tumours or melanoma who have no other treatment options. The study aims to find a safe and tolerable dose, and to see if the drug can shrink tumours. Participants receive the drug every three …

This pilot study explores whether people with melanoma or non-small cell lung cancer that has spread to the brain can safely skip stereotactic radiosurgery (focused radiation) after having a brain tumor surgically removed. Instead of radiation, participants receive systemic thera…

This study is testing a new experimental drug called GI-101, given alone or with pembrolizumab or lenvatinib, in people with advanced or metastatic solid tumors (cancers that have spread). The goal is to see if the drug is safe and can shrink or control tumors. About 317 adults w…

This study tests whether adding an antibody drug called hu14.18K322A to standard chemotherapy helps children with high-risk neuroblastoma, a rare but aggressive childhood cancer. About 144 children and teens aged 18 months to 18 years will receive the combination over up to 12 cy…

This early-phase trial tests a new treatment for children and young adults with medulloblastoma or similar brain tumors that have come back or not responded to standard therapy. The treatment uses the patient's own immune cells, modified to recognize and attack tumor cells, deliv…

Researchers are testing whether combining SX-682, an experimental drug that blocks CXCR1 and CXCR2, with proton craniospinal irradiation is safe and effective for people with leptomeningeal disease from melanoma or non-small cell lung cancer. Participants take SX-682 by mouth twi…

This study looks at how a highly targeted form of radiation called stereotactic radiosurgery (CyberKnife) works alongside newer treatments like immunotherapy and targeted therapy for people with melanoma that has spread to the brain. Researchers will observe 50 patients over time…

This study is testing whether giving radiation therapy along with immunotherapy before surgery can improve outcomes for people with sinonasal or anorectal mucosal melanoma, two rare and aggressive cancers. About 40 participants will receive combination immunotherapy (such as ipil…

This study tests a drug called tebentafusp in people with a specific type of advanced eye cancer (uveal melanoma) that has spread to other parts of the body. The drug is designed to help the immune system attack cancer cells. Researchers will also use a blood test to measure tumo…

This early-phase study tests a new radioactive drug, 225Ac-ETN029, in 116 adults with advanced DLL3-positive cancers like small cell lung cancer or neuroendocrine tumors. The main goal is to check safety and find the right dose, while also seeing if the drug can shrink tumors. Pa…

This study tests whether adding AGuIX gadolinium-based nanoparticles to standard brain radiation can better control brain metastases that are at high risk of coming back. About 134 adults with certain cancers (like melanoma, lung, breast, or colorectal) that have spread to the br…

This study tests a new treatment called DOC1021 for people with advanced melanoma that has not responded to standard therapy. DOC1021 is a personalized vaccine made from a patient's own blood and tumor cells, designed to teach the immune system to attack the cancer. The trial wil…

This early-stage study aims to develop a personalized treatment for children with syndromic craniosynostosis, a group of rare genetic disorders where skull bones fuse too early. The approach uses a nano-engineered gel to deliver custom genetic medicine directly to the affected ar…

This trial tests whether combining bexmarilimab with nivolumab can help people whose cancers no longer respond to immunotherapy. It focuses on two cancers: non-small cell lung cancer and melanoma. The study first finds the safest dose of bexmarilimab to give with a fixed dose of …

This study tests a combination of two drugs, trametinib and azacitidine, for children newly diagnosed with juvenile myelomonocytic leukemia (JMML), a rare blood cancer. Lower-risk patients get just these two drugs, while higher-risk patients also receive standard chemotherapy. Th…

This study tests whether specially grown donor immune cells (called cytotoxic T lymphocytes) can safely and effectively control BK and JC virus infections in people with weakened immune systems, such as those with cancer, HIV, or organ transplants. About 100 participants will rec…

This early-stage study tests a new medicine called PF-08046033 in adults with advanced lung, esophageal, or skin cancers that have spread or can't be removed. The main goal is to check safety and find the right dose. Researchers will also look for early signs that the drug may he…

This study tests two oral drugs, AMXT 1501 and DFMO, given alongside standard treatments for people with advanced solid tumors (breast cancer or melanoma) that have worsened after prior therapies. The goal is to find a safe dose and see if the combination helps shrink tumors or s…

This study is for children newly diagnosed with high-risk neuroblastoma, a rare and aggressive nerve cancer. It uses genetic testing to choose personalized chemotherapy, then tests whether adding the drug DFMO to standard immunotherapy helps prevent relapse. About 500 children wi…

This study tests an experimental pill called silmitasertib combined with standard chemotherapy in children and young adults (under 30) whose solid tumors (like neuroblastoma, Ewing sarcoma, or osteosarcoma) have come back or not responded to treatment. The goal is to find a safe …

This phase 2 study tests belzutifan, a daily pill that blocks a protein called HIF-2α, in people with advanced rare cancers like pheochromocytoma/paraganglioma, pancreatic neuroendocrine tumors, VHL disease-associated tumors, and certain other solid tumors. The goal is to see if …

This study tests whether adding the immunotherapy drug sintilimab to standard chemotherapy can help prevent a rare type of skin cancer (mucosal melanoma) from coming back after surgery. About 220 adults with PD-L1-positive, completely removed tumors will be randomly assigned to g…

This early-phase study tests whether a new cell therapy called B7-H3 CAR T cells is safe and can help children and young adults whose solid tumors have returned or stopped responding to standard treatments. About 40 participants will receive their own immune cells that have been …

This study tests two oral drugs, eflornithine (DFMO) and AMXT 1501, in children and young adults up to age 26 with certain cancers that have come back or not responded to treatment. The cancers include neuroblastoma, brain tumors, and sarcomas. The goal is to find a safe dose and…

This study tests a new pill called tipifarnib combined with an FDA-approved drug, naxitamab, for people with neuroblastoma that has come back or not responded to treatment. The goal is to see if the combination is safe and helps shrink tumors or slow the disease. The trial is for…

This study tests a new drug called BNT326, given alone or with other cancer immunotherapies, in about 980 adults with advanced solid tumors that have spread or come back after prior treatment. The goal is to find the best dose and see if it is safe and effective. It is an early-s…

This early-phase trial is testing a new drug called KIN-2787 (exarafenib), alone or combined with another drug (binimetinib), in 400 adults with advanced solid tumors that have BRAF or NRAS mutations. The main goals are to check safety, find the best dose, and see if the drug can…

This phase 2 trial tests whether injecting two experimental immune drugs, L19IL2 and L19TNF, directly into tumors can help people with advanced melanoma that no longer responds to standard immunotherapy. Participants receive one of the injected drugs or a combination of both, alo…

This study tests whether combining a liver-directed chemotherapy (HEPZATO KIT) with an immunotherapy drug (Opdualag) is safe and effective for people with metastatic melanoma that has spread to the liver. About 15 participants who have not received prior systemic treatment will r…

This study tests a new way to deliver radiation therapy for people with lung cancer, melanoma, or kidney cancer that has started to grow again in a few spots despite treatment. The approach uses a PET scan to find the most active parts of the tumor and delivers a higher radiation…

This study tests a combination of two immunotherapy drugs (nivolumab and ipilimumab) along with two anti-rejection medications (sirolimus and prednisone) in kidney transplant recipients who have advanced skin cancer that cannot be surgically removed or has spread. The goal is to …

This phase 2 trial tests a new treatment called LM103 TILs, made from a patient's own immune cells, for advanced melanoma that hasn't responded to standard therapies. About 92 adults will be randomly assigned to receive either the TIL therapy or standard care. The study aims to s…

This phase 2 trial is testing whether a reduced chemotherapy regimen called N10 is safe and effective for children with high-risk neuroblastoma. The study will enroll 45 children under 19 years old who have not had more than one prior chemo cycle. The goal is to see if this light…

This trial tests whether combining three immunotherapy drugs, nivolumab, relatlimab, and ipilimumab, can safely and effectively treat metastatic melanoma as a first-line therapy. Researchers will enroll about 30 adults with advanced melanoma to find the best dose of the triplet a…

This study tests whether freezing part of a growing tumor (cryoablation) can help two immunotherapy drugs, ipilimumab and nivolumab, work better in people with advanced melanoma that has stopped responding to initial treatment. About 37 adults whose melanoma is growing despite pr…

This study tests whether adding a drug called pembrolizumab to a special type of radiation therapy can help prevent mucosal melanoma from returning after surgery. About 20 people with this rare head and neck cancer will receive the combination. The goal is to see if this approach…

This study tests whether one dose of the immunotherapy drug pembrolizumab, given before standard surgery, can shrink or eliminate tumors in people with stage IIb/c melanoma. About 30 adults with thick melanomas that haven't spread to lymph nodes will receive either pembrolizumab …

This phase 2 trial tests a radioactive drug called Lu-177-DOTATATE in 130 adults with rare adrenal or neck tumors that cannot be surgically removed. The drug is given four times over about 8 months, and researchers track how long the cancer stays under control. The goal is to see…

This study tests a drug called tegavivint in children, teens, and young adults whose solid tumors have come back or stopped responding to treatment. The goal is to find the safest dose and see if it can shrink tumors by blocking a key growth signal inside cancer cells. About 147 …

This Phase 2 study tests an oral drug called RLY-2608 in adults and children with overgrowth conditions (like CLOVES or Klippel-Trenaunay syndrome) caused by PIK3CA gene mutations. The drug is designed to block the faulty protein driving abnormal tissue growth. The trial will enr…

This study is testing the drug T-DXd (Enhertu) in 100 adults with advanced HER2-positive solid tumors who have already tried other treatments and have no good options left. The goal is to see how well the drug works in real-world settings, including how many patients respond and …

This early-phase study is testing two drugs together — alpelisib and pembrolizumab — in people with metastatic breast cancer or melanoma that has spread to the brain or other organs. The main goal is to find a safe dose and see what side effects occur. Up to 50 adults whose cance…

This study tests whether adding a radioactive drug (131I-MIBG) or a targeted pill (lorlatinib) to standard intensive therapy helps children and young adults with newly diagnosed high-risk neuroblastoma live longer without the cancer returning. About 750 participants aged 1 to 30 …

This early-phase trial tests a new drug called STC-15, either alone or combined with an immunotherapy drug (toripalimab), in people with advanced solid tumors or certain sarcomas. The study aims to check safety and whether the drugs shrink tumors. About 107 participants will be e…

This study tracks how well the drug Koselugo (selumetinib) works and what side effects it causes in people with Neurofibromatosis Type 1 and painful nerve tumors. About 200 patients in South Korea will be followed during their normal doctor visits. The goal is to confirm the drug…

This study tests whether a simple blood test that looks for tumor DNA (ctDNA) can help doctors decide when to add a third immunotherapy drug (ipilimumab) to a two-drug combination (nivolumab and relatlimab) for people with advanced melanoma. About 90 adults with metastatic or adv…

This phase 2 trial tests whether specially trained donor immune cells, called CIML-NK cells, can be safely given to 20 children and young adults (ages 1-39) with relapsed or refractory neuroblastoma. The cells are made from a half-matched donor and infused alongside standard dinu…

This early-stage trial tests whether two cancer drugs, cabozantinib and selumetinib, can safely shrink plexiform neurofibromas in people aged 16 and older with neurofibromatosis type 1 (NF1). About 30 participants will receive the combination daily. The study first finds the safe…

This trial tests AVT32-DRL_PB, a biosimilar (copy) of the cancer drug Keytruda, in 120 people with stage IIB/C or III melanoma whose tumors were fully removed. Half get the biosimilar, half get Keytruda, every 3 weeks. The main goal is to see if drug levels in the blood are simil…

This early-phase trial tests a combination of three drugs—selumetinib, ZEN-3694, and durvalumab—in people with advanced sarcomas, including malignant peripheral nerve sheath tumors (MPNST) linked to NF1. The study first checks safety and dosing, then looks at whether the treatmen…

This Phase 1 trial tests two experimental mRNA immunotherapies, mRNA-4106 and mRNA-4200, in about 42 people with advanced solid tumors. Unlike personalized cancer vaccines made from a patient's own tumor mutations, these are off-the-shelf therapies designed to target shared antig…

This trial is testing whether two experimental oral drugs, APG-115 and APG-2575, can help people with neuroblastoma or other solid tumors that have returned or not responded to standard treatment. The study will first find the safest dose, then expand to see how well the drugs wo…

This early-phase trial is exploring whether a radioactive drug called [211At]MABG, given in several smaller doses, is safe and tolerable for children with neuroblastoma that has relapsed or not responded to treatment. The study will include about 10 participants aged 1 year and o…

This study tests a personalized vaccine made from a patient's own tumor proteins, given alone or with the immunotherapy drug pembrolizumab. The goal is to see if the combination is safe and helps the immune system attack advanced solid tumors. About 132 people with various advanc…

This phase 2 trial tests whether adding an experimental immune-boosting pill (PRTX007) to standard immunotherapy (pembrolizumab) before surgery can improve outcomes for people with stage III melanoma. About 48 adults with resectable melanoma will take the combination for 9 weeks …

This study tests an experimental oral drug called VMD-102 in people with advanced solid tumors, including liver, lung, kidney, skin (uveal melanoma), and colorectal cancers that have not responded to standard treatments. The drug works by blocking a specific protein (PKC epsilon)…

This Phase 3 trial tests a one-time cell therapy called IMA203 for people with advanced melanoma that has not responded to prior treatment. IMA203 is made from a patient's own immune cells and is designed to target cancer cells. The study compares IMA203 to standard treatments li…

This early-phase trial is testing an experimental oral drug called GIM-531, alone or with an immunotherapy (anti-PD-1), in 117 adults with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if the drug is safe, tolerable, and can help th…

This early-stage trial tests a new type of cell therapy for children whose embryonal tumors (rhabdomyosarcoma, Ewing sarcoma, neuroblastoma, or Wilms tumor) have returned or not responded to standard treatments. The therapy uses the patient's own immune cells, engineered to bette…

This trial investigates whether giving standard combination immunotherapy (ipilimumab and nivolumab) in the early morning (before 10 AM) versus the afternoon (after 1 PM) improves tumor response in people with advanced melanoma. About 170 participants with metastatic or inoperabl…

This trial tests whether a six-month program of supervised resistance exercise and personalized nutritional support can help adults with stage II to IV melanoma preserve muscle mass and quality while starting immunotherapy. Participants are randomly assigned to either the exercis…

This early-stage study tests a new drug called KUP-101A in 21 people with advanced skin cancers (like melanoma or Merkel cell carcinoma) that have not responded to other treatments. The main goals are to find the safest dose and check for side effects. Researchers will also measu…

This trial tests an experimental drug called STAR0602, which is designed to help the immune system attack cancer cells. It is being studied in people with advanced solid tumors that have not responded to standard treatments. The drug is given alone or combined with chemotherapy, …

This early-stage study tests a new drug called JL19001 in people with advanced solid tumors or a type of lymphoma that has come back or not responded to treatment. The main goal is to find a safe dose and check for side effects. About 14 participants will receive the drug as a sh…

This study tests a new treatment called afamitresgene autoleucel in children and young adults aged 2 to 21 with advanced cancers that have a specific marker (MAGE-A4). The treatment uses the patient's own immune cells, modified to attack the cancer. The main goals are to check sa…

This phase 2 trial is testing whether adding hydroxychloroquine—a drug commonly used for malaria—to a MEK inhibitor (tunlametinib) and an immunotherapy (pucotenlimab) can improve outcomes for people with advanced NRAS-mutant melanoma. The study aims to see if this combination can…

This study looks at whether giving radiation to the lymph nodes after surgery can lower the chance of melanoma returning in people who are already receiving immunotherapy. About 168 adults with high-risk melanoma that has spread to a sentinel lymph node will take part. The goal i…

This early-stage trial is testing an experimental drug called MBS8(1V270), given alone or with the immunotherapy pembrolizumab, in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety and find the right dose. About 1…

This study investigates whether aggressive lipid-lowering therapy can reduce plaque buildup in the heart arteries of melanoma patients starting immune checkpoint inhibitors (ICIs). Participants with plaque detected on a heart CT scan are randomly assigned to either usual care or …

This trial is testing an investigational drug called ARV-6723, given as a pill, in people with advanced solid tumors. The drug is designed to help the immune system recognize and attack cancer cells. The study will test ARV-6723 alone and in combination with pembrolizumab, an imm…

This study offers access to a radioactive therapy called 131I-MIBG for people with neuroblastoma or pheochromocytoma that has returned or stopped responding to standard treatments. The therapy is designed to seek out and deliver radiation directly to tumor cells. Researchers are …

This trial is testing an experimental therapy called STX-003, which uses mRNA to produce a protein that may help the immune system fight cancer. It is given intravenously, either alone or with the immunotherapy drug pembrolizumab (Keytruda). The study involves adults with advance…

This trial tests an experimental drug called KLS-1, a form of zinc aspartate enriched with a specific zinc isotope, in adults with certain solid tumors (like melanoma, prostate, or pancreatic cancer) or chronic lymphocytic leukemia (CLL). The goal is to find the safest and most e…

This Phase 2 trial tests a new treatment called GC101 TIL for people with advanced melanoma that has not responded to standard therapies. The treatment uses immune cells taken from the patient's own tumor, grown in a lab, and then given back to fight the cancer. About 98 particip…

This early-stage study tests whether giving children with high-risk solid tumors a special type of immune cell (called TAA-T) is safe. The cells are designed to recognize and attack proteins found on tumor cells. Up to 36 children whose cancer has not responded to standard treatm…

This early-phase study tests a new drug (PLN-101095) alone or with pembrolizumab in adults whose advanced solid tumors have stopped responding to standard immunotherapy. About 124 participants will receive the treatment to check safety and early signs of tumor shrinkage. The goal…

This early-phase trial is testing whether adding sitagliptin, a diabetes drug, to the immunotherapy pembrolizumab is safe and can help people with advanced kidney cancer or melanoma whose cancer has stopped responding to standard treatment. The study will first find the safest do…

This phase II trial is testing an experimental drug called IBI363 in people with advanced melanoma that has worsened after at least one prior treatment. The study aims to see whether IBI363 is safe and can shrink tumors or slow their growth. About 180 participants will receive IB…

This phase 2 trial tests an oral drug called HLX-1502 in people aged 12 and older with neurofibromatosis type 1 (NF1) who have plexiform neurofibromas—nerve tumors that can cause pain, disfigurement, or other problems. The study will enroll 25 participants and measure whether the…

This study explores whether being physically active can help melanoma patients avoid or lessen the immune-related side effects of immunotherapy drugs like pembrolizumab and nivolumab. Researchers will track the activity levels of 160 adults starting immunotherapy and monitor them…

This Phase 1 trial tests whether HLX18, a biosimilar of the cancer drug OPDIVO, works similarly in people with esophageal, melanoma, or bladder cancer after their tumors have been surgically removed. About 174 participants will receive either HLX18 or OPDIVO to compare how the dr…

This trial is testing whether combining two drugs—selumetinib and APG-115—can help people with neurofibromatosis type 1 (NF1) who have nerve sheath tumors that are either pre-cancerous or already cancerous. The study aims to find a safe dose and see if the combination can shrink …

This trial investigates whether adding dried chicory root fiber to standard immunotherapy helps people with advanced melanoma. The fiber is meant to increase beneficial gut bacteria, which may in turn improve immune cell activity and the body's response to treatment. About 70 par…

This trial tests a new drug called N17350, a modified enzyme injected directly into tumors, in adults with advanced solid tumors that have not responded to standard treatments. The study aims to find the safest and most effective dose, and to see if the drug can shrink or stop tu…

This trial offers a radioactive drug called 131I-MIBG to children and adults with advanced neuroblastoma that has not responded to standard treatments. The drug is designed to seek out and deliver radiation directly to tumor cells. The goal is to provide palliative control of the…

This early-stage trial is testing a new cancer vaccine called BNT116, alone or with other drugs, in people with advanced non-small cell lung cancer. The main goal is to find a safe dose and check for side effects. About 320 participants will be enrolled across several groups, inc…

This Phase 3 trial tests an oral drug called KP-001 in 150 people aged 2 and older with venous malformations, lymphatic malformations, or KTS/CLOVES syndrome. Participants receive either KP-001 or a placebo for 24 weeks, then everyone gets the drug for another 28 weeks. The goal …

This study tests a new drug called PEEL-224, alone or with standard chemotherapy, in children and young adults whose solid tumors have not responded to treatment or have returned. The first part finds the safest dose, and the second part measures how well the drug combination shr…

This phase 2 trial tests injecting two immunotherapy drugs (ipilimumab and nivolumab) directly into melanoma tumors before surgical removal. The goal is to shrink or eliminate the cancer while reducing the severe side effects that can occur when these drugs are given through a ve…

This study tests whether adding the drug tarlatamab to standard radiation therapy is safe for people with cancers that have a protein called DLL3, including melanoma, lung cancer, and glioblastoma. About 30 adults with advanced or returning cancers will receive tarlatamab infusio…

This trial investigates whether giving oral antibiotics before elective colorectal surgery reduces complications like infections and bowel leaks in children. About 74 children scheduled for procedures such as colostomy closure or pull-through for conditions like Hirschsprung dise…

This study tests an experimental treatment called OBX-115 for people with advanced melanoma or non-small cell lung cancer that has spread or stopped responding to standard therapy. OBX-115 uses a patient's own immune cells (tumor-infiltrating lymphocytes) that are modified in the…

This phase 1 trial tests whether giving the immunotherapy naxitamab more slowly, alongside standard chemotherapies irinotecan and temozolomide plus sargramostim, can reduce side effects in children with relapsed or refractory neuroblastoma. The study enrolls about 18 patients who…

This phase 1 trial tests a drug called 177Lu-DTPA-omburtamab, which delivers radiation directly to tumor cells in children and teens with recurrent or refractory medulloblastoma or other central nervous system (CNS) tumors that have spread. The drug targets a protein called B7-H3…

This early-stage trial is testing whether injecting a flu vaccine directly into melanoma tumors can help shrink them. The study includes adults with stage I to IV melanoma who have at least one tumor that can be injected. The main goals are to find the safest dose and to see what…

This study tests whether giving a tetanus-diphtheria or polio vaccine during standard immunotherapy can help the immune system better attack melanoma tumors. About 25 adults with advanced melanoma will receive one of these vaccines after four cycles of checkpoint inhibitor therap…

This study tests pembrolizumab, a drug that helps the immune system fight cancer, in children aged 6 months to 18 years with advanced melanoma, solid tumors, or lymphoma that has spread, returned, or not responded to other treatments. The main goal is to see if the drug can shrin…

This study is for people whose melanoma has come back after standard treatment. Researchers want to see if giving two immunotherapy drugs (ipilimumab and nivolumab) before surgery can shrink the tumor and improve outcomes. About 25 adults will receive two cycles of these drugs, t…

This phase 1 trial tests a new drug called AWT020, given alone or with other cancer treatments, in people with advanced solid tumors such as non-small cell lung cancer, colorectal cancer, kidney cancer, and melanoma. The main goals are to check the drug's safety, find the best do…

This early-phase study tests a new oral drug, RLY-8161, designed to block a specific cancer-driving protein called NRAS. It is for people with advanced melanoma or other solid tumors that have an NRAS mutation and have not responded to standard treatments. The main goals are to f…

This early-phase trial tests whether giving two immunotherapy drugs (nivolumab and ipilimumab) before eye removal surgery is safe and feasible for people with high-risk uveal melanoma, a rare eye cancer. Fifteen participants will receive the drugs, then have their eye removed. Th…

This early-stage trial tests a personalized cell therapy for children with recurrent neuroblastoma or newly diagnosed DIPG, two aggressive cancers. The treatment uses the child's own immune cells (dendritic cells and T cells) and stem cells, trained to attack their specific tumor…

This phase 3 trial tests whether the drug tebentafusp can prevent uveal melanoma from coming back in high-risk patients after their initial treatment. About 290 people with a specific genetic marker (HLA-A*02:01) will either receive weekly infusions of tebentafusp or be observed …

This study tests whether removing only the largest affected lymph node (instead of all nearby lymph nodes) after 6 weeks of standard immunotherapy works just as well for stage III melanoma. About 1500 adults with stage IIIB-D melanoma will be randomly assigned to one of the two s…

This Phase 3 trial is testing whether a powerful combination of two treatments works better than standard immunotherapy alone for people with advanced melanoma that has not been treated yet. The experimental approach uses lifileucel, a personalized therapy made from a patient's o…

This phase 2 trial is testing whether adding common diabetes drugs (metformin or rosiglitazone) to standard immunotherapy (nivolumab or pembrolizumab) can improve treatment for several advanced solid tumors, including melanoma, lung cancer, and liver cancer. About 72 participants…

This trial investigates whether combining two drugs, camrelizumab and famitinib, can help people with rare head and neck cancers that have spread or cannot be removed by surgery. The study includes four types of these cancers and aims to see how safe and effective the treatment i…

This study tests whether giving the drug cemiplimab before lymph node surgery can prevent Merkel cell carcinoma from spreading to nearby lymph nodes. About 135 adults with early-stage cancer will receive either the drug or a placebo before their scheduled biopsy. The goal is to s…

This phase 1 trial tests an experimental drug, DXC006, in people with advanced solid tumors (like small cell lung cancer and neuroblastoma) or blood cancers (like multiple myeloma) who have not responded to standard treatments. DXC006 is an antibody-drug conjugate designed to del…

This study tests whether custom 3D-printed titanium implants can safely and effectively rebuild facial bones in 30 adults with defects from injury, cancer surgery, or birth conditions. Each implant is designed from CT scans to match the patient's unique anatomy. Researchers will …

This early-phase trial tests a new drug called ADCT-701 in adults with rare cancers like neuroendocrine tumors, adrenal cancer, and malignant peripheral nerve sheath tumors. The goal is to find the safest dose and see if it can shrink tumors or slow disease. Participants receive …

This study tests a new device that delivers a special type of radiation directly into skin tumors. The goal is to see if it can shrink or control the cancer. The study is for adults with certain types of skin cancer, including squamous cell carcinoma and basal cell carcinoma. Par…

This early-stage trial is testing a new drug called AB821 in 50 adults with advanced melanoma or other solid tumors that respond to immune therapies. The main goal is to check safety and find the right dose. Participants receive AB821 by IV every 2 or 3 weeks for up to two years.

This early-phase trial is testing a new treatment called MEM-288, a virus designed to infect and kill cancer cells while also boosting the immune system. The study involves 40 adults with advanced solid tumors, including lung, skin, and breast cancers, who have not responded to s…

This Phase 2 trial tests whether adding thymosin alpha 1 to the immunotherapy drug toripalimab can help elderly patients (60+) with advanced melanoma. The study will enroll 55 participants and measure how many patients' tumors shrink or disappear. Researchers also want to see if …

This study tests a new treatment called IOV-4001 for people with advanced melanoma or non-small-cell lung cancer. The treatment uses a patient's own tumor-fighting immune cells, which are collected, genetically modified to remove a 'brake' called PD-1, and then infused back after…

This study looks at whether getting standard immunotherapy in the morning (before 11 am) or afternoon (after 12 pm) changes how well it fights advanced or metastatic solid tumors. Researchers think the body's internal clock (circadian rhythm) might affect immune activity. About 1…

This phase 2 trial tests the drug avapritinib in 50 adults with advanced solid tumors that have mutations in the CKIT or PDGFRA genes. The drug blocks enzymes that help cancer cells grow. The main goal is to see how many patients' tumors shrink or disappear. Researchers will also…

This study looks at whether taking a standard immunotherapy drug (PD-1 inhibitor) on an intermittent schedule works as well as taking it continuously for people with advanced melanoma that cannot be removed by surgery. About 614 participants will be randomly assigned to one of th…

This study tests a new drug called IDE196 in people with certain cancers that have specific genetic mutations (GNAQ/11 or PRKC fusions). The cancers include metastatic uveal melanoma, cutaneous melanoma, and colorectal cancer. The trial has two phases: first to find safe doses, t…

This early study tests whether giving an IL-17 blocker (secukinumab) alongside restarting immunotherapy can lower the risk of severe immune-related side effects in people with advanced melanoma. Only 4 participants who previously had side effects like colitis or rash will be enro…

This study is for people with high-risk melanoma who have tiny bits of tumor DNA still in their blood after surgery. It compares a two-drug immunotherapy combo against a single drug to see which better clears these hidden cancer cells. About 54 participants will be randomly assig…

This program provides the experimental drug ulixertinib to people with advanced solid tumors that have certain gene mutations (MAPK pathway). It is for patients who have not responded well to or have run out of standard treatments. The goal is to control the disease and possibly …

This study tests a new treatment made from donor immune cells (CAR-NK cells) that are designed to attack two targets on melanoma cells. It is for adults with advanced melanoma that has spread or cannot be removed and has not responded to standard therapies. The goal is to find a …

This study is testing a combination of two drugs—a targeted radioactive drug (177Lu-DOTATATE) and a PARP inhibitor (olaparib)—in children and teens aged 3 to 18 with certain solid tumors that have come back or not responded to treatment. The goal is to see if the combination is s…

This early-stage trial tests a new drug called MST-0312, designed to help the body's immune system fight cancer more effectively. It is being studied alone or with another cancer drug (pembrolizumab) in people with several types of solid tumors, including lung, melanoma, bladder,…

This Phase II trial tests two experimental drugs, JS212 and JS213, alone or together, in 410 adults with advanced solid tumors (kidney, prostate, bladder, or skin cancer). The main goal is to see if the drugs shrink tumors. Researchers will also check safety and how long any bene…

This study tests whether removing a smaller border of healthy tissue around a melanoma (narrow excision) works as well as the standard wider excision. About 1,000 adults with early-stage melanoma will be randomly assigned to one of the two surgeries. The goal is to see if narrow …

This early-phase trial tests whether adding an experimental drug called CBL0137 (Curaxin) to standard immunotherapy (ipilimumab and nivolumab) is safe for people with advanced melanoma that has spread. Only 12 participants will be enrolled, and the main goal is to check for side …

This early-phase trial is testing whether a combination of two drugs—cadonilimab and a high-dose interferon—can safely shrink tumors in people with stage III or IV melanoma before they have surgery. Ten participants will receive the drugs for three months, and researchers will mo…

This program offers early access to a combination of two immunotherapy drugs, botensilimab and balstilimab, for people with serious or life-threatening cancers like colorectal, pancreatic, lung, liver, melanoma, sarcoma, ovarian, or prostate cancer. It is for patients who have tr…

This study tests a new drug called Becotatug Vedotin in children aged 2 to 18 with certain solid tumors that have come back or spread. The drug targets a protein called EGFR found on many cancer cells. The main goal is to see if the drug is safe and to find the best dose, while a…

This early-phase trial is testing a new treatment called LauT-1 for people with advanced melanoma or sarcoma that has not responded to standard therapies. LauT-1 is made by taking a patient's own immune cells, modifying them in a lab to better recognize and attack their cancer, a…

This study tests a new treatment for people with solid tumors that have come back or not responded to standard care. The treatment uses a patient's own immune cells (T-cells) that are genetically modified in a lab to recognize and attack a protein called PRAME found on cancer cel…

This study tests a stem cell transplant for people with common variable immunodeficiency (CVID) and other immune disorders. The goal is to replace the faulty immune system with a healthy donor's stem cells. Participants are aged 5 to 40 and will receive a reduced-intensity transp…

This study is testing whether a low branched-chain amino acid (BCAA) diet, when combined with an immunotherapy drug (anti-PD-1), is safe and effective for people with stage III melanoma. About 80 participants will receive either the special diet or a normal diet alongside the imm…

This study tests a combination of drugs (liposomal mitoxantrone, capecitabine, and anlotinib) in children, adolescents, and young adults whose solid tumors have returned or not responded to previous treatments. The goal is to see if this regimen can shrink tumors or stop them fro…

This early-phase trial is testing a new type of immunotherapy called B7-H3 CAR T cells in children and young adults whose solid tumors (such as neuroblastoma, sarcoma, or osteosarcoma) have come back or not responded to standard treatments. The therapy involves taking a patient's…

This early-stage trial tests whether injecting gold nanoparticles into tumors, followed by radiation and an immunotherapy drug, is safe for people with advanced melanoma. Only 6 participants will be enrolled. The goal is to check for side effects, not to see if the treatment work…

This phase 2 trial is testing whether adding a precise type of radiation called SBRT to standard immunotherapy helps people with advanced melanoma that has spread to a few spots live longer. About 129 adults with untreated, stage IV melanoma will either get immunotherapy alone or…

This study tests whether feeding babies with congenital gastrointestinal issues (like gastroschisis or Hirschsprung disease) only human milk helps them reach full feeds faster than standard care, which may include formula. Researchers will also look at gut bacteria and infection …

This study tests whether combining two drugs—regorafenib (a targeted therapy) and envafolimab (an immunotherapy)—can help people with advanced GIST that has a specific gene change (KIT exon 17 mutation) and has stopped responding to standard treatments. About 100 adults will be r…

This study looks at whether adding a precise form of radiation (stereotactic radiosurgery) to standard drug therapy can better control brain metastases in people with melanoma or non-small cell lung cancer. About 180 participants with newly diagnosed, untreated brain metastases w…

This study tests an experimental drug called REGN10597, alone or with another drug (cemiplimab), in people with advanced solid tumors like melanoma and kidney cancer. The goal is to see if the treatment is safe and can shrink tumors. About 240 participants will receive the drug i…

This study tests a program called Pediatric Medication Therapy Management (pMTM) for children with complex medical conditions who take five or more medications. The program involves a thorough review of all medicines, optimizing the regimen, and creating a clear medication plan. …

This study tests a combination of two drugs—pembrolizumab (an immunotherapy that helps the immune system fight cancer) and lutetium Lu 177 dotatate (a radioactive drug that kills cancer cells)—in 18 adults with Merkel cell carcinoma. The goal is to see if the combination can shri…

This study tests giving chemotherapy and immunotherapy before standard surgery for head and neck cancer. The goal is to shrink tumors enough so that surgeons can perform less extensive, function-preserving operations, reducing damage to swallowing, speech, and vision. The trial e…

This early-stage trial tests whether adding a new drug called roginolisib to the existing treatment tebentafusp can help people with advanced uveal melanoma, a rare eye cancer. The study involves 8 adults whose cancer has spread and who are already on tebentafusp. The main goal i…

This program gives patients with advanced melanoma access to AMTAGVI, a cell therapy, even when the manufactured batch doesn't meet commercial standards but is still considered safe. It's for people who are already eligible for AMTAGVI and have a product made for them that failed…

This early-phase study tests an experimental oral drug called NST-628 in adults with advanced solid tumors that have specific genetic changes in the MAPK pathway. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors. About 230 partic…

This study tests whether people with melanoma can safely avoid a second surgery (re-excision) after the initial tumor is removed with clear margins. About 1,749 adults with stage pT1b to pT4b melanoma will be randomly assigned to either standard follow-up care including re-excisi…

This study tests the drug nivolumab in people with advanced rare cancers that have a specific marker (PD-L1). The goal is to see if the drug can shrink or control the tumors when other treatments have stopped working. Up to 28 adults will receive treatment for up to 12 months, an…

This early-phase trial tests a four-drug combination—vorinostat plus three chemotherapy drugs—in children, teens, and young adults up to age 30 whose solid tumors or brain cancers have returned or not responded to standard treatment. The main goal is to find the safest dose of vo…

This phase IIa trial is testing two experimental drugs, HX009 and IN10018, given together with or without standard chemotherapy, in 124 adults with advanced solid tumors, specifically biliary tract cancer and melanoma. The study aims to find the best dose and see if the combinati…

This early-phase study tests an injection of a modified herpes virus (RP1) directly into high-risk melanoma tumors. The goal is to see if it can kill cancer cells and reduce the chance of the cancer spreading to nearby lymph nodes. About 25 adults with thick or ulcerated melanoma…

This expanded access program provides 131 I-MIBG therapy for children and young adults with refractory or relapsed neuroblastoma, a cancer that hasn't responded to standard treatments. The therapy uses a radioactive compound that is taken up by cancer cells, delivering radiation …

This study tests a drug called mirdametinib in adults with neurofibromatosis type 1 (NF1) who have skin tumors called cutaneous neurofibromas. The goal is to find a safe dose and see if the drug can shrink these tumors. About 24 people will take the drug daily or on a three-week-…

This study tests a treatment called electrochemotherapy for people with tumors in organs like the liver or pancreas that cannot be removed by surgery. The treatment uses short electrical pulses to help chemotherapy drugs enter cancer cells more effectively. The goal is to shrink …

This study follows 120 Israeli children and teens with type 1 diabetes who use the Medtronic 780G system, a closed-loop insulin pump that automatically adjusts insulin. Researchers will track blood sugar control, sleep, diet, and emotional well-being over two years. The goal is t…

This early study tests a personalized mRNA vaccine (mRNA-0523-L001) for people with advanced endocrine tumors like adrenal cancer, medullary thyroid cancer, and pancreatic neuroendocrine tumors who have no standard treatment left. The vaccine is made to target unique mutations in…

This study tests a special stem cell transplant for children and adults with blood cancers like leukemia. The transplant uses stem cells that have had certain immune cells removed to lower the risk of graft-versus-host disease, a serious complication. About 70 participants will r…

This early-stage trial is testing a new treatment called VET3-TGI, a virus designed to infect and destroy cancer cells. It is being given alone or with the immunotherapy drug atezolizumab to 60 people with advanced solid tumors that have not responded to standard treatments. The …

This study tests a new treatment for children and young adults with neuroblastoma that has returned or not responded to standard care. The treatment uses specially engineered immune cells from donated cord blood that are designed to recognize and attack two different markers on t…

This study looks at thinking and mental health issues in people with Velocardiofacial, Williams, and Fragile X syndromes. Researchers will test how well medications like methylphenidate, fluoxetine, and risperidone improve these symptoms. The goal is to better understand and trea…

This study is testing a bone marrow transplant from a half-matched family donor for people with high-risk solid tumors that have come back or not responded to treatment. Participants receive mild chemotherapy and radiation before the transplant, along with drugs to prevent reject…

This study is testing whether giving one dose of the immunotherapy drug pembrolizumab six weeks before surgery can help the immune system fight high-risk melanoma more effectively. About 49 adults with melanoma that hasn't spread on scans will receive the drug, then have their ly…

This study tests whether adding a low-dose chemotherapy drug (cyclophosphamide) to an immunotherapy (pembrolizumab) can shrink tumors in people with advanced melanoma that has stopped responding to standard immunotherapy. About 14 adults with stage III or IV melanoma that cannot …

This large phase 3 trial is testing whether giving immunotherapy for 6 months after surgery for high-risk melanoma is as effective as the standard 12-month course. The study aims to enroll 1,792 adults who have had their melanoma surgically removed. If shorter treatment works, it…

This phase 2 trial is testing two oral drugs, belvarafenib and cobimetinib, in about 45 people with advanced or spreading melanoma that has a specific genetic change called an NRAS mutation. The goal is to see if the combination can shrink tumors and keep the disease under contro…

This study is for people with metastatic melanoma whose cancer has started growing in a few spots despite treatment. Researchers want to see if giving high-dose, precise radiation to those spots can delay further spread. About 52 adults will take part, and the main goal is to see…

This study tests a drug called tunlametinib in people with advanced melanoma that has a specific NRAS gene change and has not responded to prior immunotherapy. About 110 adults will take the drug by mouth to see if it can shrink tumors and how safe it is. The goal is to control t…

This study tests whether adding low-dose radiation to the liver before standard immunotherapy can help people with melanoma or non-small cell lung cancer that has spread to the liver. About 21 participants will receive radiation before their first three immunotherapy cycles. The …

This study tests whether adding an experimental drug (IMC-F106C) to standard immunotherapy (nivolumab) works better than standard treatment alone for people with advanced melanoma. About 680 adults with a specific genetic marker (HLA-A*02:01) and previously untreated advanced mel…

This study tests whether combining a targeted immunotherapy (tebentafusp) with a liver-directed radiation treatment (Y-90 radioembolization) can help control metastatic uveal melanoma that has spread to the liver. About 30 adults whose cancer is mainly in the liver and who have a…

This study tests a new drug, tebentafusp, alone or with pembrolizumab, in people with a specific genetic type (HLA-A*02:01) of advanced melanoma that has been treated before. The main goal is to see if these treatments help people live longer compared to other available options. …

This expanded access program provides the drug DFMO to children and young adults up to age 30 with rare relapsed tumors such as neuroblastoma or medulloblastoma. The goal is to control the disease by targeting specific genetic markers. Participants take DFMO by mouth twice daily,…

This study tests a new approach using immune cells from healthy donors, engineered to recognize and attack cancer cells. The target is chosen based on each participant's tumor profile. The trial includes 85 adults with advanced solid tumors that have not responded to standard tre…

This study tests whether combining two drugs, axitinib and nivolumab, can shrink or control advanced mucosal melanoma that hasn't been treated before. About 20 adults with this rare cancer will receive the combination. The goal is to see if the drugs work better together than alo…

This study tests whether giving new combinations of immunotherapy drugs before surgery can improve outcomes for people with advanced melanoma that is hard to treat. About 494 participants with stage 3 skin or mucosal melanoma will receive different drug combinations before their …

This phase 2 trial is testing whether the immunotherapy drug pembrolizumab (Keytruda) can shrink Merkel cell carcinoma before surgery and lower the risk of it returning afterward. About 15 people with stage I to III Merkel cell carcinoma that can be surgically removed will receiv…

This study tests a new treatment called EBNK-001, made from donor immune cells (natural killer cells), in people with advanced solid tumors that have not responded to standard therapies. Participants receive the cells after chemotherapy to prepare the body, along with low-dose in…

This early-phase trial is testing a new drug called 177Lu-RAD204, which is a radioactive antibody designed to seek out and destroy cancer cells that have a protein called PD-L1 on their surface. The study will involve 30 adults with advanced solid tumors (like lung, breast, or sk…

This study tests a new daily pill called YCT-529 for male contraception. It involves 88 healthy men who have decided not to have children. The pill is taken for 28, 90, or 180 days to check its safety, side effects, and how well it works. This is an early step toward giving men a…

This study is for people with stage IV melanoma that has spread to the brain. It compares two treatments: a combination of two immunotherapy drugs (ipilimumab and nivolumab) alone, or the same drugs plus precise, targeted radiation to the brain tumors. The goal is to see if addin…

This phase 3 trial tests a powerful mix of chemotherapy, immunotherapy, and the child's own natural killer (NK) cells for children aged 1.5 to 18 with high-risk neuroblastoma that didn't respond or came back. The goal is to shrink tumors and improve survival by helping the immune…

This early-phase trial is testing a new drug called TGI-5, given alone or with the immunotherapy nivolumab, in people with advanced solid tumors such as colorectal, liver, lung, and skin cancers. The study aims to find safe doses and check for side effects in about 194 participan…

This study tests a new drug called TCC1727 combined with other medicines (benmelstobart, olaparib, or topotecan) in people with advanced solid tumors, including lung, stomach, endometrial cancer, and melanoma. The goal is to find the safest dose and see if the combination helps s…

This trial is testing several combinations of existing drugs (dinutuximab beta, bevacizumab, irinotecan, and temozolomide) in children whose neuroblastoma has come back or not responded to standard treatment. About 160 participants will be randomly assigned to different treatment…

This early-stage trial tests a new drug called ONM-501, which is injected directly into tumors, either alone or with the immunotherapy cemiplimab (Libtayo). The study includes 168 adults with advanced solid tumors or lymphomas that have not responded to standard treatments. The m…

This early-phase trial is testing whether giving children with advanced neuroblastoma or osteosarcoma a special type of immune cell (gamma delta T cells) from a healthy donor, along with several standard cancer drugs, is safe and tolerable. The study will enroll 24 children aged …

This Phase 3 trial tests whether injecting Daromun directly into melanoma tumors before surgery can help prevent the cancer from returning. About 186 people with stage IIIB/C/D melanoma will either get Daromun injections plus standard surgery and follow-up therapy, or just surger…

This study tests two different immunotherapy treatments given before surgery for stage III melanoma that can be removed. One group gets a single drug (PD-1 blocker), the other gets a two-drug combo (PD-1 and CTLA-4 blockers). The combo may work better but also has more side effec…

This study is testing a procedure called EUS-RFA, which uses a thin needle guided by ultrasound to heat and destroy small tumors in the pancreas or adrenal glands. About 138 participants will receive this treatment as part of their standard care and be followed for up to 5 years.…

This study tests two or three drugs (defactinib, avutometinib, and possibly encorafenib) in people with advanced melanoma that has spread to the brain. The goal is to see if these combinations can shrink brain tumors and how safe they are. About 33 adults whose melanoma worsened …

This study tests an experimental drug called NBM-BMX in people with metastatic uveal melanoma, a rare eye cancer that has spread to other parts of the body. The goal is to find the best dose, check for side effects, and see if the drug can shrink or slow tumors. Participants take…

This study follows 40 people who received Miltenyi CAR T cell therapy at least one year ago for cancers like melanoma, lymphoma, or leukemia. Researchers will track side effects, cancer return, and overall health for years. The goal is to understand the long-term safety and effec…

This trial is testing two drugs, vemurafenib and cobimetinib, already approved for melanoma, in adults with other rare cancers that have a specific genetic change called BRAF V600 mutation. The goal is to see if the combination can shrink tumors or stop them from growing. About 3…

This early-phase study tests a new drug called LB-LR1109 in people with advanced solid tumors like lung, kidney, head and neck, bladder, or skin cancer that has not responded to standard treatments. The study first gives the drug alone, then in combination with another cancer dru…

This trial tests capmatinib, a drug already approved for certain lung cancers, in adults with rare cancers that have specific MET gene changes. About 30 participants will receive the drug to see if it can shrink tumors or stop them from growing for at least 24 weeks. The goal is …

This trial tests the drug entrectinib (Rozlytrek) in people with rare cancers that have a specific genetic change called ROS1 fusion. The drug is already approved for some lung cancers, but researchers want to see if it works for other tumor types. About 30 adults, teens, and chi…

This trial tests atezolizumab, a drug already approved for several cancers, in people with rare cancers that have high tumor mutational burden (TMB) or microsatellite instability (MSI). The goal is to see if the drug can shrink tumors or stop them from growing for at least 24 wee…

This study tests a drug called alectinib, already approved for some lung cancers, in people with rare cancers that have a specific genetic change called ALK. About 30 adults, teens, and children with ALK-positive cancers will receive alectinib to see if it shrinks tumors or stops…

This study tests an experimental treatment for adults with advanced melanoma who are already getting immunotherapy and planning surgery. The treatment combines focused ultrasound (using sound waves to heat and destroy tumor tissue) with an injection of a drug called polyICLC that…

This phase 2 trial is testing a two-step treatment for people with BRAF-mutated melanoma that has spread to the brain and is causing symptoms. First, participants take two targeted pills (encorafenib and binimetinib) for about two months. Then, they receive two immunotherapy drug…

This early-stage trial tests a new approach for children with neuroblastoma that has come back or not responded to standard treatment. Researchers take the child's own natural killer T cells, add genes to help them recognize and attack neuroblastoma cells, and give them back alon…

This study tests whether a dietary supplement called Oral Impact® can lower the risk of severe side effects from immunotherapy drugs used to treat advanced melanoma. Twenty patients with inoperable locally advanced or metastatic melanoma will take the supplement for 35 days, star…

This study is testing whether removing only the cancerous lymph node in people with stage III melanoma can prevent the cancer from returning in that same area. Participants have one detectable cancerous lymph node and will undergo surgery to remove it, with or without additional …

This study tests the drug belzutifan in 100 people with von Hippel-Lindau (VHL) syndrome, a genetic condition that causes tumors in various organs. Researchers will track how well the drug shrinks tumors and how long it takes for the disease to progress, while also monitoring sid…

The ORACLE study watches people who have finished treatment for early-stage solid tumors, such as lung, breast, colon, and pancreatic cancers. Researchers want to see if a blood test called Guardant Reveal can find tiny traces of tumor DNA that might signal the cancer is coming b…

This trial is testing whether a new radioactive tracer, called 68Ga-SorB, can help doctors see certain solid tumors on PET/CT scans. The tracer targets sortilin, a protein that is often found on cancer cells. About 50 adults with melanoma, liver, lung, breast, pancreatic, or ovar…

This trial is investigating whether a new radioactive tracer called 18F-grazy-02, used with PET/CT scans, can safely and effectively monitor how well immunotherapy is working in people with lymphoma or solid tumors. The tracer targets granzyme B, a protein released by immune cell…

This study tests whether a rapid triage test (suPAR) can help doctors make better decisions about admitting or discharging children with fever. Over 5,000 children aged 2 months to 5 years in sub-Saharan Africa will be randomly assigned to standard care or standard care plus the …

This study tests a new type of PET scan that uses a special tracer (Ga68-PSMA) to see if it can tell the difference between a growing tumor and radiation damage in people with brain metastases from lung cancer, melanoma, or breast cancer. About 100 adults who have had radiation t…

This study is testing a new device that uses light and sound to detect melanoma cancer cells flowing in the blood, without needing a blood draw. The goal is to see if it can find these cells faster and more sensitively than current lab tests. About 75 people with melanoma will be…

This study is testing a new blood test that looks for fetal cells in the mother's blood to detect genetic conditions like Down syndrome. The test will be compared to standard diagnostic methods such as amniocentesis or newborn testing. The study involves 1,000 pregnant individual…

This study tests whether a new type of PET scan using a radioactive tracer called 18F-FCH can more accurately locate overactive parathyroid glands or tumors before surgery. About 193 adults scheduled for parathyroid removal will receive both the new scans and a standard 4D-CT sca…

This study tests a new type of PET/CT scan using a radioactive tracer called 68Ga-DOTATATE to see if it can detect neuroblastoma tumors better than the current standard scan (123I-MIBG). The study will enroll 20 children and young adults with suspected or confirmed neuroblastoma.…

This study looks at whether a blood test for a protein called hPG80 can help find neuroendocrine tumors (NETs) earlier in people with MEN1, a genetic condition that raises tumor risk. About 297 participants with MEN1 will give blood samples, which will be compared to standard ima…

This study tests a new radioactive imaging agent called 68Ga-HA-DOTATATE to see if it can safely and accurately detect neuroendocrine tumors using PET/CT scans. About 600 people with known or suspected tumors will receive the agent and be followed for one year. The goal is to imp…

This study is testing a new radioactive imaging agent that targets a protein called LRRC15, found on many cancer cells. Researchers will use PET scans to see if this agent can better detect and stage cancers like pancreatic, breast, lung, and others. The trial includes 26 healthy…

This study compares a dye called ICG alone against the standard two-method approach (ICG plus a radioactive tracer) to find cancer in lymph nodes of women with early vulvar cancer. About 58 women will take part. If ICG alone works just as well, it could simplify surgery and reduc…

This study will screen 13,000 children in China using urine tests and ultrasound to find kidney disease early. The goal is to see how common kidney problems are in kids and to build a system to predict who is at risk. Children with abnormal results will be referred for further ca…

This study is testing whether a telemedicine tool can help primary care doctors find skin cancer earlier. About 1,440 people with suspicious moles or lesions will have their skin checked remotely. The goal is to see if this approach can spot malignancies that might otherwise be m…

This study is testing a new platform that uses advanced testing to get a complete picture of a person's tumor. The goal is to see if this detailed information can help doctors choose better treatments for patients with high-risk cancers like leukemia, multiple myeloma, and pancre…

This phase 3 study is testing an improved PET/CT imaging method using a radioactive tracer called 18F-DOPA. Researchers want to see if it can better detect small lesions and reduce image artifacts in patients with conditions like congenital hyperinsulinism, neuroblastoma, neuroen…

This study tests a special dye called anti-GD2-800CW that makes neuroblastoma cells glow during surgery. About 22 children with neuroblastoma will receive a single dose of the dye before their operation. The goal is to find the safest and most effective dose to help surgeons see …

This study is testing a new blood test that looks for DNA fragments from tumors in people with hereditary cancer syndromes like Lynch syndrome or BRCA mutations. The goal is to see if the test can find cancers earlier than standard screening methods. Researchers will compare canc…

This study tests whether a special PET/MRI scan using a radioactive tracer called Ga68-DOTATATE can better detect certain brain tumors (like meningioma) and tell them apart from changes caused by past treatments. About 200 adults with these tumors will get the scan alongside stan…

This phase 2 trial is testing whether a new radioactive tracer, [68Ga]Ga-FAPI-46, can improve how doctors evaluate response to immunotherapy in patients with stage IV melanoma. Twenty participants will receive two experimental PET/CT scans—one before starting immunotherapy and on…

This study is testing whether an AI-powered smartphone app (NuvanaDx) can accurately detect skin cancer, including melanoma, by analyzing photos of suspicious moles or lesions. About 100 adults with concerning skin spots will take part. The goal is to see if the app can help catc…

This study looks at two lab tests (RT-qPCR and ddPCR) to find leftover cancer cells in frozen ovarian or testicular tissue from children treated for neuroblastoma or Ewing sarcoma. The goal is to make it safer for these children to later use their stored tissue to have children o…

Researchers are testing whether sulforaphane, a substance found in broccoli and other cruciferous vegetables, can prevent melanoma in people who have multiple atypical moles and a prior history of melanoma. Participants take sulforaphane or a placebo by mouth. The trial measures …

This trial tests whether vedolizumab, a drug that calms inflammation in the gut, can prevent diarrhea and colitis caused by immune checkpoint inhibitors. People with advanced melanoma, lung, or kidney cancer who are starting immunotherapy and show early signs of gut inflammation …

This phase 3 trial tests whether two different eye treatments can prevent vision loss in people who have had radiation therapy for a type of eye cancer called uveal melanoma. The study will compare faricimab injections given every 3 months, a fluocinolone acetonide implant placed…

This study tests a sun protection program for children playing baseball in rural Utah and West Virginia. Researchers will observe whether kids on teams using the program apply sunscreen, wear hats and long sleeves, and seek shade more often than those on teams that don't. The goa…

This study tests five different smartphone programs designed to help melanoma survivors reduce unprotected sun exposure. About 150 participants will wear a UV sensor and activity monitor, complete daily surveys, and use the programs for 8 weeks. The goal is to see which programs …

This phase 2 trial tests whether the drug quisinostat can prevent uveal melanoma from spreading in high-risk patients. About 63 people who have completed initial treatment for their eye tumor will take quisinostat capsules three times a week. Researchers will track how long parti…

This study tests whether giving selumetinib early to children with NF1, before nerve tumors cause symptoms, can prevent tumor growth and related problems. About 200 children aged 1 to 8 years with no known tumors will either receive the drug or be observed. The goal is to see if …

This study tests a new method called U-CaVIT, which uses a balloon placed in the uterus to prevent severe bleeding after a C-section in women at high risk. About 70 participants will either get standard care or standard care plus the balloon. The goal is to see if the balloon red…

This trial tests whether botulinum toxin type A injections can improve lower-lip asymmetry in children with hemifacial microsomia, a condition where the lower lip moves unevenly during smiling or speaking. The study enrolls children under 18 with this condition and a crooked-mout…

This trial tests whether two simple distractions — watching a betta fish or playing with a hand puppet — can lower pain, fear, and anxiety in children aged 5 to 7 during a blood draw. One group will use the fish, another the puppet, and a third will receive standard care. Researc…

This study compares a new radiation technique called lattice radiation therapy (LRT) to standard stereotactic body radiation therapy (SBRT) for people with solid tumors that have spread to soft tissues. The goal is to see if LRT shrinks tumors better and helps the immune system f…

This pilot trial tests a new approach to support cancer patients and their caregivers. The intervention combines social prescriptions—connecting people to community resources—with short online learning modules and regular symptom check-ins. The goal is to see if this package can …

This study tests whether Acceptance and Commitment Therapy (ACT), delivered through a smartphone app, can help caregivers of children with RASopathies (like Neurofibromatosis type 1 and Noonan syndrome) cope with parenting stress. The trial is fully remote and involves 70 adult c…

This study tests whether an AI-based website that gives personalized diet tips and recipes can help cancer patients who experience taste changes during therapy. About 198 adults with certain cancers (like multiple myeloma, melanoma, or GI cancers) will either get the AI tool or a…

This study tests a drug called fezolinetant to see if it can reduce hot flashes in men with prostate cancer who are on hormone therapy (androgen deprivation therapy). About 60 men will take either the drug or a placebo daily for 4 weeks. Researchers will track hot flash frequency…

This study tests whether a digital tool combining weekly symptom surveys and a Fitbit can help monitor patients during immunotherapy for advanced melanoma. Forty participants will be randomly assigned to use the tool or receive usual care. The goal is to see if the system is easy…

This trial tests whether sertraline, a widely used antidepressant, can reduce anxiety in children and teens aged 8 to 17 with neurodevelopmental disorders such as autism, ADHD, Fragile X syndrome, and Tourette syndrome. Participants receive either sertraline or a placebo for seve…

This study tests whether adding telephone health coaching to a symptom management handbook helps reduce symptom burden and improve quality of life for people with metastatic breast, GI, or melanoma cancer and their caregivers. About 200 participants will be split into two groups:…

This study tests whether riluzole, a drug already used for ALS, can help cancer survivors who struggle with memory, focus, and mental clarity after treatment — a condition called cancer-related cognitive impairment. Researchers will measure changes in a brain protein called BDNF …

This study looks at whether a 12-week supervised exercise program can reduce fatigue and improve quality of life in adults with stage IIb-IV melanoma who are receiving immunotherapy or targeted therapy. Participants are randomly assigned to either an exercise group (online sessio…

This study compares two surgical techniques—perforator flap versus skin graft—for repairing the wound left after removing a stage II melanoma. Researchers want to see which method leads to faster wound healing and better quality of life. Forty adults with melanoma on the trunk, a…

This study follows 350 people with stage III-IV melanoma during their first two years after diagnosis to understand how their quality of life and mental health change. It also tests whether cognitive behavioral therapy for cancer distress (CBT-C) can help reduce stress, improve s…

This study tests whether playing Kho-Kho, a traditional Indian tag game, can improve agility and reaction time in school children aged 8 to 12. Over 6 weeks, 48 kids will either play Kho-Kho or do free play three times a week. Researchers will measure changes in agility and react…

This study looks at whether a fermented whey protein and fiber supplement can improve digestive comfort in recreational athletes. Researchers will enroll 114 participants, some with and some without stomach complaints, and compare the supplement to a placebo. The goal is to see i…

This study tests whether a short bout of cycling exercise right before immunotherapy (nivolumab and ipilimumab) can boost the immune system and improve treatment outcomes in people with advanced melanoma. Researchers want to see if this approach is practical and safe for patients…

This Phase 2 trial tests a single oral dose of LY4515100 against a placebo in 212 people with moderate-to-severe pain after having their wisdom teeth removed. The goal is to see if the drug safely reduces pain intensity and how quickly it works. Participants stay in a research un…

This study compares two approaches to supportive cancer care for nearly 3,000 adults with cancer. One group gets information through email or their health record, while the other works one-on-one with a lay health worker over 12 months. The goal is to see which model better impro…

This study looks at whether people with certain cancers prefer getting their immune therapy as a shot under the skin (subcutaneous) or through a needle in a vein (intravenous). About 880 adults who are already eligible for standard treatments like nivolumab or pembrolizumab will …

This study is testing a treatment called sacral neuromodulation, which uses mild electrical pulses to stimulate nerves that control the bowel and bladder. The goal is to see if it can reduce symptoms like severe constipation, stomach pain, and loss of bowel control in children ag…

This study tests whether EMLA numbing cream can reduce pain from Technetium 99 injections used in lymphoscintigraphy, a standard mapping procedure for skin cancers like melanoma. About 100 adults with skin cancer will receive either EMLA cream or a placebo before the injection. T…

This study looks at children with congenital melanocytic nevi (large birthmarks) who choose to have them surgically removed. Researchers want to see if removal improves quality of life and reduces feelings of being stigmatized. About 100 children aged 9 months to 16 years will be…

This study looks at whether the Alexander technique, a method that teaches better posture and movement habits, can help children aged 5 to 9 with Duchenne muscular dystrophy control their upper limbs and feel better day-to-day. About 33 kids will take part, and researchers will m…

This study tests whether sensory exercises can improve repetitive behaviors, communication, social interaction, and motor skills in children with autism. About 26 children aged 5 to 11 will take part. Researchers will measure changes using standard questionnaires before and after…

This study looks at whether adding a special support program (called RISE) to usual care can reduce financial and material hardships for low-income families of children with high-risk neuroblastoma. About 84 children and their parents will take part, with half getting the extra s…

This study tests whether playing with a therapeutic toy doll before getting a shot can reduce fear, anxiety, and pain in children aged 4-6. Half the kids will practice the injection steps on a doll first, while the other half get the shot as usual. Researchers will measure fear a…

This study tests whether a mindfulness-based emotion regulation training program can help children aged 7-11 who are hospitalized for at least four days feel less afraid and better control their emotions. Half of the 54 participants will receive the training alongside usual care,…

This study tests whether urolithin A, a dietary supplement, can improve the immune system's response to standard immunotherapy drugs in people with newly diagnosed solid tumors like lung cancer or melanoma. 45 participants will be randomly assigned to receive either urolithin A o…

This study looks at whether doing adapted physical activity every day can improve sleep quality in children aged 5 to 16 who are being treated for blood cancer. About 30 children will take part, with some exercising daily and others just once over four days. Parents will track sl…

This study tests whether fecal microbiota transplantation (FMT) capsules can help people with diarrhea and colitis caused by immune checkpoint inhibitor cancer treatment. About 20 adults with melanoma or kidney cancer will receive either FMT or placebo capsules alongside their st…

This study collects moles and blood samples from 50 adults to analyze the genetic mutations that cause moles to form. Researchers will compare DNA from mole tissue with normal DNA from blood to find specific changes. No treatments or interventions are given—the goal is purely to …

This study follows up to 3,000 people who have, are at risk for, or are related to someone with a parathyroid disorder. Researchers will collect medical records, questionnaires, and samples like blood and saliva to learn what causes these conditions and how they change over time.…

This study works to improve questionnaires that measure pain, daily activities, and physical function for people with neurofibromatosis type 1 (NF1) who have plexiform neurofibromas. Participants aged 5 and older will give feedback on existing surveys through group discussions or…

This study collects biological samples—like blood, skin biopsies, and swabs—from people with or at risk for skin diseases, as well as healthy volunteers. Researchers will use these samples to study the causes of skin conditions and explore potential treatments. Up to 700 particip…

This study aims to improve how doctors find and understand pheochromocytomas and paragangliomas, rare tumors that can cause dangerous high blood pressure. Researchers will use advanced imaging scans and genetic testing in up to 3,000 participants to learn more about these tumors.…

This study enrolls people with endocrine tumors (such as thyroid, parathyroid, adrenal, or pancreatic tumors) who are scheduled for surgery or biopsy. Researchers collect samples of the tumor, nearby healthy tissue, blood, and urine to analyze genetic and molecular changes. The g…

This study is testing whether smartwatches and blood tests can measure how well children recover after surgery to remove a solid tumor. About 40 children and their caregivers will wear smartwatches and answer questionnaires before surgery and for up to a year after. Researchers w…

This study is a disease registry that will collect information from 200 people in Egypt who have neurofibromatosis type 1 (NF1), a genetic condition that causes tumors to grow on nerves. The goal is to understand how the disease progresses over time, what treatments patients rece…

This study aims to understand how genetics and environmental factors contribute to melanoma, a serious skin cancer. Researchers will enroll up to 3,000 people with a personal or family history of melanoma or related conditions. Participants will fill out questionnaires, provide b…

This study is creating a registry of up to 1,000 people with rare lymphatic system disorders. Researchers will collect information from medical records and yearly surveys to understand how these diseases progress, what treatments are used, and how they affect quality of life. The…

This observational study in Vietnam looks at archived tumor samples from patients with several solid cancers, including liver, colorectal, gastric, breast, lung, endometrial, melanoma, and pancreatic cancer. Researchers will measure the presence of two proteins, ENPP1/cGAS and FA…

This study screens adults with certain cancers (like melanoma, lung, or colorectal cancer) to see if they qualify for experimental treatments being tested by the NCI Surgery Branch. These treatments involve taking a patient's own immune cells, growing them in a lab, and giving th…

This study collects extra blood, urine, and tumor samples from children and adults with certain cancers to build a large tissue repository. Researchers will analyze these samples to learn more about the genetic and molecular makeup of these tumors. The goal is to support future s…

Researchers are building an international registry to collect health information from people with congenital central hypoventilation syndrome (CCHS), a rare condition that affects breathing control. The study asks patients with a confirmed PHOX2B gene mutation to fill out surveys…

This study measures thinking, memory, and attention in people with congenital central hypoventilation syndrome (CCHS), a rare condition that can reduce oxygen to the brain. Participants complete a 45-minute app-based cognitive assessment on an iPad, and parents or adult participa…

This study is for people aged 3 and older with neurofibromatosis type 1 (NF1), a genetic condition that often causes noncancerous nerve tumors. About half of people with NF1 get these tumors, and sometimes they turn cancerous. Researchers want to test a new method to predict whic…

This study looks at whether using genetic markers from a child's skin tumor can help doctors decide how much surgery is needed. About 51 children and young adults up to age 25 with localized melanoma or similar growths will have their tumor tissue reviewed centrally. Based on ris…

This study follows about 1,400 people with coronary heart disease who undergo a stent procedure, called PCI, to open blocked arteries. Even with standard treatment, these patients still face a risk of major heart events. Researchers will measure levels of a protein called hsCRP, …

This study collects blood and tissue samples from 2000 people—some with cancer and some without—to create a blinded reference set. Researchers will use these samples to evaluate how well new blood tests can detect many types of cancer early. The goal is to improve the accuracy of…

This study creates a registry of medical records, scans, and surveys from adults with neurofibromatosis type 1 (NF1) who also have a glioma brain tumor. Researchers will track diagnosis, treatments, and quality of life over time to better understand the disease. The goal is to im…

This study follows 819 children under 2 years old who have medium to giant congenital nevi (pigmented birthmarks). Researchers will track neurological development, melanoma risk, and quality of life over time. The goal is to create better monitoring and treatment guidelines for t…

This study collects information from 200 adults in Russia who have neurofibromatosis type 1 (NF1) with plexiform neurofibromas. Researchers will look at patients' age, symptoms, and medical history to better understand the disease. No new treatments are being tested; the goal is …

This study is a large registry that collects health information and leftover tumor or blood samples from up to 75,000 children and young adults with cancer. The goal is to track outcomes and gather data to help doctors find better ways to treat and care for these patients over ti…

This study tests tumor tissue from up to 12,000 cancer patients to find gene changes (mutations). The goal is to match each patient with a clinical trial or therapy that targets their specific cancer type. Researchers will also build a database of mutations to help future patient…

This study enrolls 7,000 people with various cancers who have had or will have treatment aimed at a cure. Researchers collect blood, tissue, urine, and saliva samples over time to look for tiny bits of cancer DNA left behind. The goal is to find any remaining cancer as early as p…

This study will follow 600 people with early-stage solid cancers (like lung, head and neck, melanoma, or bladder cancer) who are receiving immunotherapy before surgery. Researchers will collect blood and tumor samples at several time points to see how the immune system responds. …

This study is building a large collection of blood, saliva, urine, stool, and tissue samples from people who are at increased risk of cancer, including those with genetic predispositions, survivors of childhood or adult cancer, or those with precancerous conditions. The goal is t…

This study tests whether simple reminders—called nudges—sent to doctors and patients can increase the use of genetic testing for people with certain conditions like Parkinson's disease, ALS, or heart problems. The trial will compare different ways of prompting genetic testing, su…

This study investigates whether a blood marker called anti-Müllerian hormone (AMH) can predict future infertility in children and adolescents who have undergone cancer treatment. Many young patients recover normal menstrual cycles or puberty after chemotherapy, but their ovarian …

This study is testing whether a mobile app called Vigilant can help monitor side effects in 100 people with skin cancer or melanoma who are starting a specific type of immunotherapy. Participants will use the app to report any symptoms they experience, and researchers will track …

This early-stage study tests whether people with advanced solid tumors can safely follow a diet low in methionine, an amino acid found in many proteins. Researchers will measure how well participants stick to the diet, check for side effects, and track changes in blood methionine…

22q11.2 deletion syndrome can cause heart defects, facial differences, and learning challenges, but its severity differs widely from person to person. This study analyzes DNA from 1,000 people with the deletion to identify genetic variations that might influence how the disorder …

This study looks at whether adding a high-fiber diet and short-term fasting can help melanoma patients undergoing immunotherapy. Forty participants will follow a high-fiber diet, with half also doing 72-hour fasts during each treatment cycle, while 20 others serve as a control gr…

This study tests whether a digital tool called MySmartSkin can help melanoma survivors do better skin self-exams. About 385 survivors will use either the enhanced app or a standard educational webpage. The goal is to see if the app leads to more thorough skin checks and earlier d…

This study follows 800 children born with eye malformations like microphthalmia, anophthalmia, aniridia, or anterior segment defects. Researchers will track their vision, brain development, and overall health for up to 10 years to better predict outcomes. No new treatments are be…

This study is for young adults (ages 21-45) who had certain cancers as teens or young adults. Researchers are adapting a program that helps survivors manage their health after cancer treatment. The goal is to see if this program improves survivors' confidence and ability to handl…

This study observes patients with high-risk stage II melanoma to see if starting anti-PD-1 immunotherapy before surgery leads to better outcomes compared to the usual timing after surgery. Researchers will track when patients begin systemic therapy and compare results between the…

This pilot study looks at how belzutifan, a drug already used for some tumors, changes the production of adrenaline-like hormones in people with pheochromocytoma and paraganglioma (PPGL). Over 5 days, researchers measure key substances in the hormone-making process to see if belz…

This study investigates clonal hematopoiesis (CH) — small mutations in blood cells that can arise naturally or after cancer treatment — in adults receiving chemotherapy or radiation for solid tumors like breast, lung, or colorectal cancer. Researchers will collect blood, saliva, …

This study is building a huge registry of information and biological samples from adults with or at risk for many types of cancer, as well as healthy volunteers. Researchers will use this resource to study what causes cancer and how to better prevent, detect, and treat it. The re…

This study is collecting live tumor samples from 2,000 cancer patients undergoing standard biopsies. Researchers will analyze these samples to understand how tumors respond to immunotherapy drugs outside the body. The goal is to develop a method to predict which patients will res…

This study aims to discover new genes that may cause certain cancers to run in families. Researchers will collect blood samples and health information from 1,500 people in families where multiple members have had cancer, especially childhood cancers. The goal is to build a regist…

This study looks at how to reduce the long and frustrating journey to a diagnosis for people with developmental abnormalities. Researchers will review past cases, collect new blood or skin samples, and use advanced genetic testing. The goal is to understand why some people remain…

This study tracks 770 adults with advanced solid cancers (like lung, head and neck, melanoma, or bladder cancer) who are receiving immunotherapy. Researchers collect tumor and blood samples over time to find biological markers that predict how well the treatment works or causes s…

This study is looking for certain cells in the blood of people with 9 types of advanced cancers that have spread. Researchers will take one blood sample from each of 450 participants before they start a new treatment. They will use two different lab methods to see if they can fin…

This study is collecting detailed genetic and health information from 500 people with various cancers, including breast, lung, and leukemia. The goal is to create a shared database that helps researchers develop more personalized treatments. Participants provide samples and data,…

This study looks at melanoma tumors that spread between the main tumor and nearby lymph nodes (called in-transit metastases). Researchers will take biopsies from different spots and use a safe tracer to measure oxygen levels. They aim to understand how these tumors change metabol…

This study is investigating whether low oxygen levels (hypoxia) in melanoma tumors and nearby lymph nodes are linked to worse outcomes. Researchers will give 50 patients a safe oral tracer called pimonidazole before their standard surgery. By measuring hypoxia in the removed tiss…

This pilot study explores whether eating high-fermented foods (like yogurt and kimchi) followed by high-fiber supplements can change the gut microbiome and improve immune response in people with melanoma or lung cancer who are receiving standard immunotherapy. Researchers will tr…

This study looks at whether the bacteria naturally found in urine can help doctors better understand melanoma, a serious skin cancer, and predict how well patients will respond to treatment. Researchers will collect urine and stool samples from 50 people with advanced melanoma st…

This study aims to find the genes responsible for Hirschsprung disease, a condition where nerve cells are missing from parts of the intestine. Researchers will collect DNA samples from 3,000 people with the disease and their close family members. By analyzing common and rare gene…

This study aims to collect and analyze tumor samples from 10,000 adults with advanced solid cancers (like breast, lung, or colon cancer) to create a province-wide gene database. The goal is to help doctors identify which targeted drugs or clinical trials might work best for each …

This study looks at how melanoma tumors process energy, specifically glucose, to see if certain metabolic patterns are linked to cancer spread. Researchers will give a special glucose tracer to 400 adults with melanoma before their surgery and analyze the tumor tissue. Participan…

This study is building a large French database of patients with three rare skin cancers: Merkel cell carcinoma, advanced basal cell carcinoma, and cutaneous adnexal carcinomas. Researchers will track up to 9,000 participants to learn how these cancers behave, what factors affect …

This study is testing whether an 8-minute educational video can effectively prepare cancer patients for genetic testing, compared to standard genetic counseling. Over 1,000 adults with various cancers will participate. The goal is to see if the video is acceptable and improves un…

This study enrolls 200 people with acral or cutaneous melanoma who are starting standard immunotherapy. Researchers will collect blood samples every 3 weeks and tumor tissue after about 3 months of treatment. By analyzing circulating tumor cells, DNA, and other markers, they aim …

This study is for people with advanced cancers who are taking long-term targeted treatments. Researchers want to learn about their experiences through interviews. The goal is to find better ways to support these patients. The study is currently recruiting 75 participants.

This study looks at how immunotherapy drugs (anti-PD-1) affect bone strength in people being treated for cancer. Researchers will measure bone density and blood markers over a year in 25 patients. The goal is to understand if these treatments increase fracture risk, so doctors ca…

This study collects blood, urine, and bone marrow samples from 620 people with solid cancers like lung, colorectal, and pancreatic cancer. Researchers will look for tumor cells and DNA in these samples to understand how cancer spreads and why it sometimes comes back after surgery…

This study uses online surveys to learn about the real-life experiences of people diagnosed with cancer and their caregivers. Researchers want to understand the emotional, physical, social, and financial challenges they face. The goal is to use this information to improve support…

This study aims to develop an artificial intelligence (AI) algorithm that analyzes skin damage (dermatoheliosis) around a melanoma scar to predict whether a patient will respond to anti-PD-1 immunotherapy. Researchers will collect photos and medical data from 700 adults with adva…

This study looks at whether checking for pieces of tumor DNA in the blood (called ctDNA) can help doctors see how well treatment is working and find cancer returning early in children with neuroblastoma. About 200 children with newly diagnosed or returning neuroblastoma will give…

This study aims to bring molecular markers into routine care for patients with rare adrenal cancers. Researchers will collect blood, urine, and tumor samples from 450 patients before and after surgery to see if these markers can guide treatment decisions. The goal is to make thes…

This study looks at DNA methylation patterns (chemical tags on DNA) in fetuses with rare genetic diseases. Researchers will analyze DNA from amniotic fluid and tissue samples to create reference signatures. The goal is to improve diagnosis of these conditions before birth. The st…

This study looks at how a 2-week, personalized therapy program helps children aged 4-12 with conditions like cerebral palsy, autism, or genetic disorders. Kids get about 2.5 hours of tailored therapy each day, focusing on skills like movement, attention, and communication. The go…

This study collects tissue, blood, and bone marrow samples from 1,000 children with high-risk neuroblastoma. Researchers will analyze these samples to learn more about how the cancer grows and how to detect it better. The goal is to improve future treatments and monitoring of the…

This study aims to find new genes that may cause a hereditary risk for uveal melanoma, a rare eye cancer. Researchers will analyze the DNA of 50 patients with this cancer to identify unknown genetic changes. The goal is to improve screening and surveillance for families affected …

This study follows 2,000 adults with newly diagnosed breast, colorectal, lung, melanoma, or lymphoma cancer who are receiving chemotherapy or immunotherapy. Researchers will track whether using cannabis or cannabinoids helps with symptoms like pain or nausea over time. No treatme…

This study looks back at the past 10 years to understand how a life-support machine called ECMO has been used in children across China. Researchers will gather information from 500 children, from newborns to 18-year-olds, to see how many survive after treatment, how long they nee…

This study is looking for better ways to predict who might develop or have a return of certain cancers, including breast, colon, ovarian, melanoma, and lung cancer. Researchers will collect blood samples from 850 participants to study genetic and other biological markers. The goa…

This study looks at how the liver's immune system reacts to a chemotherapy drug called melphalan, given directly to the liver through a special procedure. It involves 10 adults with uveal melanoma that has spread to the liver. The goal is to understand immune changes, not to test…

This study is looking for 500 people with certain cancers (like eye or skin melanoma, kidney cancer, or mesothelioma) and their family members to understand how common BAP1 gene mutations are. Researchers will collect medical history and questionnaires to learn about cancer risks…

This study is testing whether a blood test that looks for tumor DNA (ctDNA) can find cancer returning earlier than standard scans. About 100 people with different solid tumors will give blood samples after treatment. The goal is to see if early detection can lead to better treatm…

This study is tracking 100 people in Slovenia with advanced melanoma who are receiving first-line immunotherapy drugs like pembrolizumab, nivolumab, or ipilimumab. Researchers want to see how well these treatments work and whether a marker called PD-L1 in tumors or blood can pred…

This study tracks how choroidal melanoma and its treatment affect patients' quality of life. It involves 15 people already in a larger Phase 3 trial. Participants fill out questionnaires about their well-being over two years. No new drugs or procedures are tested here.

This study is tracking 40 people in Slovenia with metastatic melanoma who are receiving standard first-line immunotherapy. Researchers want to see how well the treatment works and look for clues in blood, stool, and tumor samples that might predict who will benefit most. The goal…

This study collects blood and tumor samples from 1,000 people with melanoma and healthy volunteers. Researchers will analyze these samples to learn more about what causes melanoma and how tumors behave. The goal is to find new markers that could lead to better diagnosis or treatm…

This study looks at how electrochemotherapy—a treatment that uses electric pulses to help chemotherapy drugs enter cancer cells—changes the environment around melanoma skin tumors. Researchers will collect tissue samples from 150 adults before and after treatment to see how immun…

This study aims to understand the full burden of 9 rare skin diseases—including physical, emotional, social, and financial challenges—on patients and their families. Researchers will use special questionnaires to track how these conditions affect daily life and care needs. About …

This study aims to create immune organoids—tiny lab-grown models of the immune system—using cells from children and young adults with brain tumors, kidney tumors, neuroblastoma, or sarcoma. Researchers will mix these organoids with tumor cells to see how they interact. The goal i…

This study aims to find the genetic causes behind certain allergic and immune system disorders. Researchers will collect blood, saliva, and tissue samples from up to 10,000 people of all ages, along with some family members. No treatments are given; the goal is simply to learn mo…

This study looks at how immune checkpoint inhibitors (ICIs), a common treatment for melanoma, may affect the reproductive organs and sex hormones in men and women. Researchers will collect blood samples and questionnaires from 80 participants during their regular treatment visits…

This study looks at how a standard immunotherapy drug (anti-PD1) changes the appearance and biology of atypical moles in people with advanced melanoma. Researchers will track 30 patients to see if the drug alters mole size, color, and cellular features. The goal is to better unde…

This study looks at 24 people with advanced melanoma who are starting immunotherapy. Researchers will do a special PET/CT scan and a blood test for tumor DNA about 3-4 weeks after the first treatment. The goal is to see if these early tests can predict whether the immunotherapy i…

This study collects blood and leftover tissue samples from 9,600 people with various cancers, including breast, lung, and pancreatic cancer. Researchers will use these samples to improve tests that look for cancer DNA in the blood. The goal is to better detect if cancer returns o…

This study watches 50 people who already received a replimune oncolytic immunotherapy for cancers like melanoma or liver cancer. The goal is to check for any delayed side effects over 5 years. No new treatment is given—just regular check-ins to see how patients are doing.

This study is for people with solid tumors that have spread to the brain. Researchers want to collect medical information and samples (like blood and spinal fluid) to better understand why and how brain metastases happen. The goal is to find new ways to treat or prevent them in t…

This study is investigating why some melanomas stop responding to immunotherapy. Researchers will take biopsies from 20 patients with advanced melanoma before and after treatment to see how tumor metabolism changes. The goal is to understand resistance mechanisms and find new way…

This study reviews medical records of 221 people with advanced melanoma who received immunotherapy between 2013 and 2021. The goal is to find new factors that predict which patients achieve a complete and lasting response. Participants must be 18 or older and have received treatm…

This observational study is looking at 25 adults aged 18 to 39 who have been diagnosed with melanoma. Researchers want to find out how common melanoma is in this age group and identify risk factors, skin features, and genetic changes linked to the disease. The goal is to better u…

This observational study in Italy will examine the link between work-related sun exposure and melanoma. Researchers will interview 300 people (120 with melanoma, 180 without) about their job history, sun habits, and protection use. The goal is to better understand how outdoor wor…

This study aims to create a large collection of blood samples from 2,500 people with or at high risk for cancer. Researchers will use these samples to study liquid biopsies, which are blood tests that may help detect cancer, track treatment response, and spot recurrence. Particip…

This study tracks 100 cancer survivors aged 18–74 to see how common muscle loss (sarcopenia) and cognitive problems ('chemo brain') are after treatment. Participants undergo physical and mental assessments. The goal is to better understand these long-term side effects and guide p…

This study tracks fertility markers in 80 melanoma patients (women aged 18-37, men aged 18-45) before, during, and after adjuvant therapy with anti-PD-1 or targeted treatments. Researchers measure hormone levels in women and sperm quality in men to see how these change over time.…

This study is testing a new cell therapy in the lab for people with Merkel cell carcinoma, a rare skin cancer linked to a virus. Researchers will take immune cells from 15 patients and try to train them to attack the cancer in a test tube. The goal is to see if this approach work…

This study collects tumor and blood samples from 1,000 children with solid cancers like neuroblastoma and sarcoma. Researchers will analyze the genetic makeup and immune response of these tumors to better understand how they grow and resist treatment. The goal is to gather knowle…

This observational study tests a new device (eMyosound LYRA) that uses sound waves to measure stiffness in the heart and liver. Researchers will compare 150 people—some with heart failure, some with a rare heart condition called ATTR-CM, and some healthy volunteers. The goal is t…

This study tests whether eating dried chicory root (a high-fiber prebiotic) every day for 6 weeks can change gut bacteria and immune cells in 20 people who had surgery for stage II melanoma. Researchers want to see if it increases helpful substances called short-chain fatty acids…

This study aims to find out if a urine test can predict acute kidney failure in intensive care patients. Researchers will measure certain substances in the urine that reflect how the body produces NAD+, a key molecule for cell energy. If successful, this could help doctors identi…

This study is testing a new predictive model that analyzes tumor samples to forecast whether a patient with melanoma or other skin cancers will respond to immunotherapy. Researchers will compare the model's predictions with actual patient outcomes over six months. The goal is to …

This study looks at whether a quick ultrasound of the thigh muscle can detect muscle loss (sarcopenia) in people who have finished cancer treatment. Researchers will compare the ultrasound results with a standard whole-body scan (DEXA) in 55 adults aged 18-74 with certain cancers…

This study follows 700 people with uveal melanoma, a rare eye cancer, who are at high risk of the cancer spreading to the liver. Participants get regular liver MRIs and blood tests to look for early signs of metastasis. The goal is to see if personalized monitoring can detect rel…